New Forces Shaping Global Pricing
Moderator
Hussain A Al-Omar, MSc, PhD, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
This session explores how US Most Favored Nation pricing, the EU Joint Clinical Assessment, and China’s 2026 drug pricing reforms are reshaping global launch strategies, evidence requirements, and access pathways. It will also examine innovative value-based pricing approaches to balance affordability, equitable access, and incentives for pharmaceutical innovation.